دورية أكاديمية
Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study
| العنوان: | Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study |
|---|---|
| المؤلفون: | Liarakos, Alexandros L, Hasan, Nebras, Crabtree, Thomas S J, Leelarathna, Lalantha, Hammond, Peter, Hussain, Sufyan, Haq, Masud, Aslam, Aisha, Gatdula, Erneda, Gibb, Fraser W, Lumb, Alistair, Bull, Kirsty, Chinnasamy, Eswari, Carrieri, Giorgio, Williams, David M, Choudhary, Pratik, Ryder, Robert E J, Wilmot, Emma G |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2024 |
| المجموعة: | University of Nottingham: Repository@Nottingham |
| مصطلحات موضوعية: | Continuous subcutaneous insulin infusion, Omnipod DASH, Tubeless insulin pump, Type 1 diabetes mellitus, Diabetes technology |
| الوصف: | AimsTo evaluate real-world outcomes in people with Type 1 Diabetes (PwT1D) initiated on Omnipod DASH® Insulin Management SystemMethodsAnonymized clinical data were submitted to a secure web-based tool within the National Health Service network. Hemoglobin A1c (HbA1c), sensor-derived glucometrics, total daily dose of insulin (TDD), and patient-reported outcome changes between baseline and follow-up were assessed. Individuals were classified to “new-to-pump” (switched from multiple daily injections) and “established-on-pump” (switched from a tethered insulin pump) groups.Results276 individuals from 11 centers [66.7 % female; 92 % White British; median age 41 years (IQR 20–50); diabetes duration 20 years (IQR 11–31); 49.3 % within “new-to-pump” group] were included. Baseline HbA1c was 8.0 ± 1.3 % (64 ± 14 mmol/mol). At follow-up [3 years (IQR 1.5–3.2)], HbA1c reduced by 0.3 % [(3 mmol/mol); p = 0.002] across the total population, 0.4 % [(5 mmol/mol); p = 0.001] in those “new-to-pump” and remained unchanged in those “established-on-pump”. TDD decreased in the “new-to-pump” cohort (baseline:44.9 ± 21.0units vs follow-up:38.1 ± 15.4units, p = 0.002). Of those asked, 141/143 (98.6 %) stated Omnipod DASH had a positive impact on quality of life.ConclusionsOmnipod DASH was associated with improvements in HbA1c in PwT1D “new-to-pump” and maintained previous HbA1c levels in those “established-on-pump”. User satisfaction in all groups and TDD reduction in those “new-to-pump” were reported. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 0168-8227 |
| العلاقة: | https://nottingham-repository.worktribe.com/output/32162174Test; Diabetes Research and Clinical Practice; Volume 209; https://nottingham-repository.worktribe.com/file/32162174/1/Real-world%20outcomes%20of%20Omnipod%20DASH%20systemTest |
| DOI: | 10.1016/j.diabres.2024.111597 |
| الإتاحة: | https://doi.org/10.1016/j.diabres.2024.111597Test https://nottingham-repository.worktribe.com/file/32162174/1/Real-world%20outcomes%20of%20Omnipod%20DASH%20systemTest https://nottingham-repository.worktribe.com/output/32162174Test |
| حقوق: | openAccess ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.B92AB2E4 |
| قاعدة البيانات: | BASE |
| تدمد: | 01688227 |
|---|---|
| DOI: | 10.1016/j.diabres.2024.111597 |